Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

18.77 -0.18 (-0.95%)
Streaming Delayed Price Updated: 3:34 PM EDT, Apr 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 608,970
Open 18.80
Bid (Size) 18.70 (2)
Ask (Size) 18.78 (1)
Prev. Close 18.95
Today's Range 18.52 - 19.78
52wk Range 13.22 - 62.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish
Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates. 
Via Stocktwits
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Pfizer bows, but is not entirely out of the GLP-1 race. 
Via The Motley Fool

Performance

YTD
-33.4%
-33.4%
1 Month
-13.9%
-13.9%
3 Month
-25.4%
-25.4%
6 Month
-48.7%
-48.7%
1 Year
-50.1%
-50.1%

More News

Read More
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Via Benzinga
The State of Weight Loss Drugs
Via The Motley Fool
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
Via Investor's Business Daily
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Why Structure Therapeutics Stock Was Stumbling This Week
Via The Motley Fool
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
AI Pharma: 2 Paths to AI-Powered Drug Investment
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
Via Benzinga
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Via Investor's Business Daily
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
Via Investor's Business Daily
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Via Investor's Business Daily
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
From Structure Therapeutics Inc.
Via GlobeNewswire
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Via Benzinga
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
Via MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Via Investor's Business Daily
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Via Investor's Business Daily

Frequently Asked Questions

Is Structure Therapeutics Inc. - American Depositary Shares publicly traded?
Yes, Structure Therapeutics Inc. - American Depositary Shares is publicly traded.
What exchange does Structure Therapeutics Inc. - American Depositary Shares trade on?
Structure Therapeutics Inc. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Structure Therapeutics Inc. - American Depositary Shares?
The ticker symbol for Structure Therapeutics Inc. - American Depositary Shares is GPCR on the Nasdaq Stock Market
What is the current price of Structure Therapeutics Inc. - American Depositary Shares?
The current price of Structure Therapeutics Inc. - American Depositary Shares is 18.77
When was Structure Therapeutics Inc. - American Depositary Shares last traded?
The last trade of Structure Therapeutics Inc. - American Depositary Shares was at 04/15/25 03:34 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.